
    
      This is a 2-part study with each part is an open-label study in healthy adult subjects.

      Total 28 subjects will be enrolled into the study and divided into 2 part (Part A and Part
      B), 14 subjects in each part. With each part, the subject will be receive study drug per the
      defined treatment periods of Day 1~7 and Day 13~19.
    
  